ACHIEVING MILESTONES. DRIVING INNOVATION. Life Sciences
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
ACHIEVING MILESTONES. DRIVING INNOVATION.
Life Sciences
There is a consistent and admirably high level of quality within the firm, as well as a very pleasant culture. These folks are exceptional lawyers and genuinely nice people
- a most winning combination of expertise and civility.
– Client quotation in Chambers USA: America’s Leading Lawyers for Business
Key Highlights
✦ Advised on the first biotechnology IPO in the Research Triangle Park region
✦ Team members possess degrees in scientific and technology-based subject matters, including biochemical sciences, engineering, physics and mathematics
✦ Lawyers serve in leadership roles at the Council for Entrepreneurial Development (CED), North Carolina Biosciences Organization (NCBIO), North Carolina Biotechnology Center and other prominent hubs of life sciences activity, including serving as former management and current directors of public life sciences companies
✦ Ready access to our lawyers who have extensive experience in IP, technology, employment, debt finance, venture capital, tax and other areas
Clients and Services
Our Life Sciences practice spans a diverse spectrum of companies ranging from large pharma to specialty pharma to biotechnology, CRO and medical device companies. We also advise leading life sciences-focused private equity and venture capital firms. Our services include:
✦ Research, development and commercialization collaborations
✦ Partnering, strategic alliance and joint venture transactions
✦ Mergers & acquisitions
✦ Product and asset acquisitions and divestments
✦ Intellectual property and technology licensing and transfer
✦ Venture capital, initial public offerings and other equity and debt financings
✦ Clinical trial and CRO arrangements
✦ Manufacturing, supply and distribution agreements
✦ Products liability, commercial and intellectual property litigation
✦ Federal grant programs (SBIR/STTR)
Cutis Pharma, Inc.(now Azurity Pharmaceuticals, Inc.)
Acquisition of SilvergatePharmaceuticals
Quotient Sciences Limited
Acquisition ofQS Pharma
Key Highlights
✦ Advised on the first biotechnology IPO in the Research Triangle Park region
✦ Team members possess degrees in scientific and technology-based subject matters, including biochemical sciences, engineering, physics and mathematics
✦ Lawyers serve in leadership roles at the Council for Entrepreneurial Development (CED), North Carolina Biosciences Organization (NCBIO), North Carolina Biotechnology Center and other prominent hubs of life sciences activity, including serving as former management and current directors of public life sciences companies
✦ Ready access to our lawyers who have extensive experience in IP, technology, employment, debt finance, venture capital, tax and other areas
Key Highlights
✦ Advised on the first biotechnology IPO in the Research Triangle Park region
✦ Team members possess degrees in scientific and technology-based subject matters, including biochemical sciences, engineering, physics and mathematics
✦ Lawyers serve in leadership roles at the Council for Entrepreneurial Development (CED), North Carolina Biosciences Organization (NCBIO), North Carolina Biotechnology Center and other prominent hubs of life sciences activity, including serving as former management and current directors of public life sciences companies
✦ Ready access to our lawyers who have extensive experience in IP, technology, employment, debt finance, venture capital, tax and other areas
Mergersand Acquisitions
R&D, Manufacturingand Commercialization
CapitalMarkets
Corporate Partneringand Licensing
Our firm is continually recognized by top legal rankings directories as leading the market.
Chiesi USA, Inc. andChiesi Farmaceutici S.p.A
Supply, distribution andclinical trial agreements
Locus Biosciences
Series A preferredstock financing
$19 million
PrecisionBioSciences
Worldwide CAR-Timmuno-oncology partnership
with Shire plc$1.6 billion
Chiesi USA, Inc. andChiesi Farmaceutici S.p.AProduct rights acquisition
and partnership withThe Medicines Company
$794 million
Mayne Pharma USA
Manufacturing, supplyand product
development agreements
Dova Pharmaceuticals
Credit facility
$20 million
United Therapeutics
License, development and commercialization agreement
with Collplantup to $44 million
NovaQuest CapitalManagement
Acquisition ofCutisPharma, Inc.
Exact Sciences Corporation
Supply and clinicaltrial agreements
Quintiles TransnationalHoldings, Inc.
Initial Public Offering
$1.09 billion
Precision BioSciences
Worldwide Hepatitis B viruslicense and development
agreement with Gilead Sciences $445 million
Cutis Pharma, Inc.(now Azurity Pharmaceuticals, Inc.)
Acquisition of SilvergatePharmaceuticals
Novan, Inc.
Clinical trial, development andmanufacturing agreements
Precision BioSciences
Initial Public Offering
$145.4 million
Locus Biosciences
Collaboration and license agreement with Janssen (J&J)
$818 million
Quintiles TransnationalHoldings, Inc.
Merger of equals withIMS Health Holdings, Inc.
$17.6 billion
Merz North America, Inc.
Distribution agreements
Novan, Inc.
Follow on public offering
$35.2 million
Chiesi Farmaceutici S.p.A
Multinational product rights transaction with Horizon
Pharma plc$72 million
plus milestone payments
Quotient Sciences Limited
Acquisition ofQS Pharma
Client ServiceA-Team for 5th
consecutive year
2020SMITH, ANDERSON, BLOUNT, DORSETT, MITCHELL & JERNIGAN, LLP
71 recognizedlawyers
Metropolitan Tier 1 for Biotechnology and Health Care
One of nine firms in the world to be recognized
in Agribusiness
Representative Transactions
Our deep industry knowledge and experience serving public and private companies is demonstrated through the following representative transactions:
Key Highlights
✦ Advised on the first biotechnology IPO in the Research Triangle Park region
✦ Team members possess degrees in scientific and technology-based subject matters, including biochemical sciences, engineering, physics and mathematics
✦ Lawyers serve in leadership roles at the Council for Entrepreneurial Development (CED), North Carolina Biosciences Organization (NCBIO), North Carolina Biotechnology Center and other prominent hubs of life sciences activity, including serving as former management and current directors of public life sciences companies
✦ Ready access to our lawyers who have extensive experience in IP, technology, employment, debt finance, venture capital, tax and other areas
Mergersand Acquisitions
R&D, Manufacturingand Commercialization
CapitalMarkets
Corporate Partneringand Licensing
Our firm is continually recognized by top legal rankings directories as leading the market.
Chiesi USA, Inc. andChiesi Farmaceutici S.p.A
Supply, distribution andclinical trial agreements
Locus Biosciences
Series A preferredstock financing
$19 million
PrecisionBioSciences
Worldwide CAR-Timmuno-oncology partnership
with Shire plc$1.6 billion
Chiesi USA, Inc. andChiesi Farmaceutici S.p.AProduct rights acquisition
and partnership withThe Medicines Company
$794 million
Mayne Pharma USA
Manufacturing, supplyand product
development agreements
Dova Pharmaceuticals
Credit facility
$20 million
United Therapeutics
License, development and commercialization agreement
with Collplantup to $44 million
NovaQuest CapitalManagement
Acquisition ofCutisPharma, Inc.
Exact Sciences Corporation
Supply and clinicaltrial agreements
Quintiles TransnationalHoldings, Inc.
Initial Public Offering
$1.09 billion
Precision BioSciences
Worldwide Hepatitis B viruslicense and development
agreement with Gilead Sciences $445 million
Cutis Pharma, Inc.(now Azurity Pharmaceuticals, Inc.)
Acquisition of SilvergatePharmaceuticals
Novan, Inc.
Clinical trial, development andmanufacturing agreements
Precision BioSciences
Initial Public Offering
$145.4 million
Locus Biosciences
Collaboration and license agreement with Janssen (J&J)
$818 million
Quintiles TransnationalHoldings, Inc.
Merger of equals withIMS Health Holdings, Inc.
$17.6 billion
Merz North America, Inc.
Distribution agreements
Novan, Inc.
Follow on public offering
$35.2 million
Chiesi Farmaceutici S.p.A
Multinational product rights transaction with Horizon
Pharma plc$72 million
plus milestone payments
Quotient Sciences Limited
Acquisition ofQS Pharma
Client ServiceA-Team for 5th
consecutive year
2020SMITH, ANDERSON, BLOUNT, DORSETT, MITCHELL & JERNIGAN, LLP
71 recognizedlawyers
Metropolitan Tier 1 for Biotechnology and Health Care
One of nine firms in the world to be recognized
in Agribusiness
Representative Transactions
Our deep industry knowledge and experience serving public and private companies is demonstrated through the following representative transactions:
SmithLaw.com/LifeSciences
Related Documents
